The goal of the Biostatistics and Bioinformatics Core is to facilitate ovarian cancer research at the Fox Chase Cancer Center and the University of Pennsylvania by providing expert experimental design, bioinformatics, data management and data analysis support to SPORE scienfists. Members of the core have substanfial knowledge and experience in biostatistics and bioinformatics as applied to cancer research. This highly interactive group of biostatisticians, bioinformatics and informaticians will serve all SPORE projects and cores and support future projects and pilot studies. The specific goals of the Biostafisfics and Biostatisfics Core are to: (1) Provide stafisfical expertise in the design of experiments and studies, including research proposal development, sample size determinafion, randomization procedures, and plans for interim reviews and final analysis;(2) Perform statisfical analyses, data explorafion, and funcfional genomics analyses. Assist in the interpretation and presentation of results;(3) Develop specialized stafistical methods by modifying existing techniques and/or developing new statisfical approaches;(4) Assist with the writing of stafistical and bioinformatics components of manuscripts;(5) Provide computer-based tools to facilitate the storage and retrieval of data generated in the proposed research, thereby creating and maintaining relafional databases that permit access to common resources and informafion. (6) Provide detailed descriptions of the available populations and resources for current and future SPORE investigators. (7) Ensure the accuracy of the data maintained in the databases by software-based data consistency and quality control systems. (8) Organize and maintain the databases to maximize accuracy and accessibility while maintaining strict confidenfiality.

Public Health Relevance

The Biostafistics and Bioinformatics Core is dedicated to the accumulafion, management, distribufion, analysis and interpretation of valuable information generated by this SPORE in Ovarian Cancer. Core members will apply their knowledge of quanfitative and computafional methods to facilitate translafional research and speed discovery and validafion of new therapeufic and prevention strategies for ovarian cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA083638-11
Application #
7727502
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2009-08-21
Project End
2014-05-31
Budget Start
2009-08-21
Budget End
2010-05-31
Support Year
11
Fiscal Year
2009
Total Cost
$141,895
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 25:1384
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Chiang, Cheryl Lai-Lai; Kandalaft, Lana E (2018) In vivo cancer vaccination: Which dendritic cells to target and how? Cancer Treat Rev 71:88-101
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7
Beck, Tim N; Smith, Chad H; Flieder, Douglas B et al. (2017) Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1. Head Neck 39:E34-E39
Yang, Lu; Zhang, Youyou; Shan, Weiwei et al. (2017) Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 9:
Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637
Zhang, Dongmei; Zhang, Gao; Hu, Xiaowen et al. (2017) Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Res 77:3745-3757
Prudnikova, Tatiana Y; Chernoff, Jonathan (2017) The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases 8:193-198

Showing the most recent 10 out of 323 publications